The Thesis
PanicFade v4 bets that negative headline shocks are overreacted to and revert toward fundamentals. Concretely, it buys names hit by sentiment below -0.4 that are already technically oversold — RSI14 under 35 and trading below their 20-day moving average — and sizes into the panic. The exit logic is symmetrical and disciplined: it takes profit on reversion (RSI14 back above 50, or price reclaiming the SMA20) and hard-stops fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
The design is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025, plus corroborating MDPI/JRFM work on stock-level investor sentiment). The universe is deliberately conservative — 24 mega-cap names spanning tech, financials, healthcare, staples, and energy — which suits a fade strategy that relies on liquidity and mean-reverting fundamentals rather than deep-value dislocation.
Recent Activity
The last week has been quiet to the point of dormant. Six consecutive scheduled runs from August 31 through September 7 each report 0 executed, 0 rejected, with cash pinned at $8,958.54 and total equity drifting narrowly between roughly $10,005 and $10,046. The only recent fill was a 10-share WMT buy at $103.115 on August 28.
That inactivity is not necessarily a flaw — a panic-fade model should sit on its hands when no name clears the sentiment-and-oversold gate. But it does mean the strategy is currently expressing almost no live conviction, and the small live equity base tells us this is a paper/experimental sleeve, not a proven live P&L record.
Backtest and Validation
The historical numbers are the strongest part of the story. Over 1,233 days and 530 trades, the backtest shows a 37.93% total return, a 6.79% CAGR, a 0.96 Sharpe, a contained 9.3% max drawdown, and a 62.88% win rate — a healthy profile for a mean-reversion book.
Validation is where it earns real credibility. Across four walk-forward folds, all four were positive, out-of-sample return was 21.7% at a 2.44 Sharpe, and the probabilistic Sharpe ratio (PSR) is 0.985 — with a deflated Sharpe of 0.56 after accounting for 27 trials. Passing the deflated-Sharpe check matters: it means the edge survives correction for multiple-testing luck.
Strengths and Risks
Strengths: clean, monotonically improving folds; a deflated Sharpe that clears the overfitting hurdle; and a coherent, literature-backed thesis with explicit, symmetric exits.
Risks worth flagging: the returns are heavily back-loaded — fold 1 (through the 2022 drawdown) returned just 1.6% at a 0.19 Sharpe, and the headline 21.7% OOS figure comes almost entirely from the most recent fold. That raises the question of whether the recent Sharpe of 2.44 is regime luck rather than durable edge. Turnover is also extreme at 5,807%, so real-world slippage and fees could erode the paper edge. And the current live inactivity leaves the strategy unproven where it counts most.